



Essential medicines in Internal Medicine: a unified list

**An initiative by the German Society of Internal
Medicine and the German subspecialty societies**

Presentation for EFIM Day 2024



Context

- Ongoing shortages threaten continuity of supply of medicines essential to the practice of internal medicine
 - Legislative measures at EU and national level to address supply shortages (e.g. EMA Shortages Monitoring Platform and Critical Medicines List, ALBVVG in Germany)
- DGIM initiative to develop a consensus list of essential medicines for internal medicine

Aim

Definition of medicines that, according to the current state of knowledge, are necessary for the treatment of internal diseases.

(No health policy initiative to specifically address the medicines that are particularly threatened by shortages.)

DGIM initiative for a list of essential medicines in internal medicine

- Development of a unified list of indispensable active substances for internal medicine
- final consensus round in progress
- cooperation with the 11 subspecialty societies of internal medicine in Germany
- approximately 600 active substances listed

Definition of essential medicines:

- **Inclusion in clinical practice guidelines (CPGs)**
- **or if not included in CPGs: current consensus on the need by at least one of the respective 11 societies**



DGIM Critical Medicines List (excerpt of the actual draft)

1	Wirkstoff	System	Wirkmechanismus Arzneistoffgruppe	Klinisch gebräuchliche Bezeichnung	ATC Cod	Leitlinie
2	BISMUTSUBCITRAT, TETRACYCLIN UND METRONIDAZOL	-	-	-	-	ja
3	BISOPROLOL	Adrenerges System	b1-Adrenozeptor (b1AR)-Antagonisten	Kardioselektive Betablocker, Antianginosa, Antihypertensiva, Antiarrhythmik	C07AB	ja
4	CARVEDILOL	Adrenerges System	a1-Adrenozeptor (a1AR)/bx-Adrenozeptor (bxAR)-Antagonis	Gemischte (duale) Alpha- und Betablocker, Antihypertensiva, Antihypertonik	C07AG	ja
5	CLONIDIN	Adrenerges System	a2-Adrenozeptor (a2AR)-Agonisten	Alpha-2-Sympathomimetika, Glaukommittel, Entwöhnungsmittel	C02AC, N02CX	ja
6	DOBUTAMIN	Adrenerges System	ax-Adrenozeptor (axAR)/bx-Adrenozeptor (bxAR)-Agonisten	Katecholamine, Adrenergika	C01CA	ja
7	DOXAZOSIN	Adrenerges System	a1-Adrenozeptor (a1AR)-Antagonisten	Alphablocker, Alpha-1-Rezeptorblocker, Antihypertensiva, Antihypertonika	C02CA	-
8	EPHEDRIN	Adrenerges System	ax-Adrenozeptor (axAR)/bx-Adrenozeptor (bxAR)-Agonisten	Katecholamine, Adrenergika	C01CA	-
9	EPINEPHRIN	Adrenerges System	ax-Adrenozeptor (axAR)/bx-Adrenozeptor (bxAR)-Agonisten	Adrenalin, Katecholamine, Adrenergika	A01AD, B02BC	ja
10	ESMOLOL	Adrenerges System	b1-Adrenozeptor (b1AR)-Antagonisten	Kardioselektive Betablocker, Antianginosa, Antihypertensiva, Antiarrhythmik	C07AB	ja
11	FENOTEROL	Adrenerges System	b2-Adrenozeptor (b2AR)-Agonisten, kurzwirksam	Bronchospasmolytika, SABA, Tokolytika, Bronchodilatator, Antiasthmatika	R03AC	-
12	FORMOTEROL	Adrenerges System	b2-Adrenozeptor (b2AR)-Agonisten, langwirksam	Bronchospasmolytika, LABA, Antiasthmatika	R03AC	ja
13	METHYLDOPA	Adrenerges System	a2-Adrenozeptor (a2AR)-Agonisten	Antihypertensiva, Alpha-Methyldopa, Antihypertonika	C02AB	ja
14	METOPROLOL	Adrenerges System	b1-Adrenozeptor (b1AR)-Antagonisten	Kardioselektive Betablocker, Antianginosa, Antihypertensiva, Antiarrhythmik	C07AB	ja
15	MOXONIDIN	Adrenerges System	Imidazolin 1 (I1)-Rezeptor-Agonist	Antiadrenergika, Antihypertensiva, Antihypertonika	C02AC	ja
16	NOREPINEPHRIN	Adrenerges System	ax-Adrenozeptor (axAR)/bx-Adrenozeptor (bxAR)-Agonisten	Noradrenalin, Katecholamine, Adrenergika	C01CA	ja
17	ORCIPRENALIN	Adrenerges System	b2-Adrenozeptor (b2AR)-Agonisten	AUßER HANDEL	-	ja
18	PROPRANOLOL	Adrenerges System	bx-Adrenozeptor (bxAR)-Antagonisten	Nicht-selektiver Betablocker	C07AA	-
19	SALBUTAMOL	Adrenerges System	b2-Adrenozeptor (b2AR)-Agonisten, kurzwirksam	Bronchospasmolytika, SABA, Bronchodilatator, Antiasthmatika	R03AC, R03CC	ja
20	SALMETEROL	Adrenerges System	b2-Adrenozeptor (b2AR)-Agonisten, langwirksam	Bronchospasmolytika, LABA, Bronchodilatator, Antiasthmatika	R03AC, R03CC	-
21	URAPIDIL	Adrenerges System	a1-Adrenozeptor (a1AR)-Antagonisten	Alphablocker, Antihypertensiva, Antihypertonika	C02CA	ja
22	XYLOMETAZOLIN	Adrenerges System	a1-Adrenozeptor (a1AR)-Agonisten	Alphamimetika, Alpha-Sympathomimetika, Dekongestiva, Schnupfenmittel	R01AA	-
23	FORMOTEROL / BUDESONID	Adrenerges System / Gluco	b2-Adrenozeptor (b2AR)-Agonisten, langwirksam / Glucocorri-	-	R03AK	ja
24	NEBIVOLOL	Adrenerges System / NO/cc	b1-Adrenozeptor (b1AR)-Antagonisten / NO-Donatoren	Antihypertensiva, Betablocker, Antihypertonika, Therapie der Herzinsuffizier	C07AB	ja
25	LEVOSIMENDAN	Aktin-Myosin-System	kardiales Troponin C (cTnC)-Agonist / Kaliumkanal-Öffner	Kardiostimulanzien	C01CX	ja
26	MAVACAMTEN	Aktin-Myosin-System	Negativer allosterischer Modulator (NAM) an kardialem Myc	Herztherapeutiks, HOCM-Therapeutika	C01EB	ja
27	BEDAQUILIN	Antibakterielle Wirkung - A	ATP-Synthase-Inhibitoren	Antituberkulotika, Tuberkulostatika	J04AK	ja
28	DELAMANID	Antibakterielle Wirkung - A	Hemmung der Mykolsäuresynthese (Dihydro-Nitroimidazo)	Antituberkulotika, Tuberkulostatika	J04AK	ja
29	ETHAMBUTOL	Antibakterielle Wirkung - A	Hemmung des Zellwandaufbaus (Dibutanol-Derivate)	Antituberkulotika, Tuberkulostatika	J04AK	ja
30	ETHAMBUTOL / ISONIAZID	Antibakterielle Wirkung - A	Hemmung des Zellwandaufbaus (Dibutanol-Derivate) / Hem	Antituberkulotika, Tuberkulostatika	J04AM	-
31	ISONIAZID	Antibakterielle Wirkung - A	Hemmung der Mykolsäuresynthese (Nikotinsäure-Derivate)	Antituberkulotika, Tuberkulostatika	J04AC	ja
32	ISONIAZID / RIFAMPICIN	Antibakterielle Wirkung - A	Hemmung der Mykolsäuresynthese (Nikotinsäure-Derivate)	Antituberkulotika, Tuberkulostatika	-	ja
33	PYRAZINAMID	Antibakterielle Wirkung - A	Hemmung bakterieller Fettsäuresynthese I (Nikotinamid-Dei	Antituberkulotika, Tuberkulostatika	J04AK	-
34	RIFABUTIN	Antibakterielle Wirkung - A	Hemmung bakterieller RNA-Polymerase (Rifamycine)	Antituberkulotika, Tuberkulostatika	J04AB	ja
35	RIFAMPICIN	Antibakterielle Wirkung - A	Hemmung bakterieller RNA-Polymerase (Rifamycine)	Antituberkulotika, Tuberkulostatika	J04AB	ja
36	RIFAXIMIN	Antibakterielle Wirkung - A	Hemmung bakterieller RNA-Polymerase (Rifamycine)	Breitbandantibiotika	A07AA, D06AX	-
37	CIPROFLOXACIN	Antibakterielle Wirkung - H	Hemmung der Topoisomerase II [DNA-Gyrase] und Topoisom	Gyrasehemmer	J01MA, S01AE	ja
38	LEVOFLOXACIN	Antibakterielle Wirkung - H	Hemmung der Topoisomerase II [DNA-Gyrase] und Topoisom	Gyrasehemmer	J01MA, S01AE	ja
39	METRONIDAZOL	Antibakterielle Wirkung - H	DNA-Schädigung (Nitroimidazole)	Anaerobiermittel	A01AB, D06BX	ja



596 substances are listed in the actual version
(EMA critical medicines list contains less than 300 substances)

DGIM - List of essential medicines for Internal Medicine

DGIM Critical Medicines List (excerpt of the actual draft)

278	ACARBOSE	Glucosestoffwechsel	alpha-Glucosidase-Inhibitoren	Orale Antidiabetika	A10BF
279	ALBIGLUTIDE	Glucosestoffwechsel	Glucagon-like peptide 1 receptor (GLP-1R)-Agonisten	Antidiabetika, Inkretin-Mimetikum, Gewichtsreduktion	A10BJ
280	ALOGLIPTIN	Glucosestoffwechsel	Dipeptidylpeptidase-4 (DPP-4)-Inhibitoren	Orale Antidiabetika	A10BH
281	CANAGLIFLOZIN	Glucosestoffwechsel	SLC5A2/Sodium dependent glucose co-transporter 2 (SGLT-2	Orale Antidiabetika, Herzinsuffizienztherapeutika, Therapeutika bei chronisc	A10BK
282	DAPAGLIFLOZIN	Glucosestoffwechsel	SLC5A2/Sodium dependent glucose co-transporter 2 (SGLT-2	Orale Antidiabetika, Herzinsuffizienztherapeutika, Therapeutika bei chronisc	A10BK
283	DIAZOXID	Glucosestoffwechsel	Kaliumkanal (ATP-sensitiv, K+(ATP), Kir6.2)-Öffner über Sulfor	Antihypoglykämika	C02DA, V03AH
284	DULAGLUTID	Glucosestoffwechsel	Glucagon-like peptide 1 receptor (GLP-1R)-Agonisten	Antidiabetika, Inkretin-Mimetikum, Gewichtsreduktion	A10BJ
285	EFPEGLENATIDE	Glucosestoffwechsel	Glucagon-like peptide 1 receptor (GLP-1R)-Agonisten	Antidiabetika, Inkretin-Mimetikum, Gewichtsreduktion	A10BJ
286	EMPAGLIFLOZIN	Glucosestoffwechsel	SLC5A2/Sodium dependent glucose co-transporter 2 (SGLT-2	Orale Antidiabetika, Herzinsuffizienztherapeutika, Therapeutika bei chronisc	A10BK
287	ERTUGLIFLOZIN	Glucosestoffwechsel	SLC5A2/Sodium dependent glucose co-transporter 2 (SGLT-2	Orale Antidiabetika, Herzinsuffizienztherapeutika, Therapeutika bei chronisc	A10BK
288	GLIBENCLAMID	Glucosestoffwechsel	Kaliumkanal (ATP-sensitiv, K+(ATP), Kir6.2)-Inhibition über Su	Orale Antidiabetika	A10BB
289	GLICLAZID	Glucosestoffwechsel	Kaliumkanal (ATP-sensitiv, K+(ATP), Kir6.2)-Inhibition über Su	Orale Antidiabetika	A10BB
290	GLIMEPIRID	Glucosestoffwechsel	Kaliumkanal (ATP-sensitiv, K+(ATP), Kir6.2)-Inhibition über Su	Orale Antidiabetika	A10BB
291	GLUCAGON	Glucosestoffwechsel	Glucagon-Rezeptor-Agonisten	Antihypoglykämika	H04AA
292	GLUCOSE	Glucosestoffwechsel	Monosaccharide	Zucker, Antihypoglykämika	B05CX, D02AX,
293	INSULIN ASPART	Glucosestoffwechsel	Insuline	Antidiabetika, Insulinanaloga	A10AB, A10AD
294	INSULIN DEGLUDEC	Glucosestoffwechsel	Insuline	Antidiabetika, Insulinanaloga	A10AE
295	INSULIN DETEMIR	Glucosestoffwechsel	Insuline	Antidiabetika, Insulinanaloga	A10AE
296	INSULIN GLARGIN	Glucosestoffwechsel	Insuline	Antidiabetika, Insulinanaloga	A10AE
297	INSULIN GLULISIN	Glucosestoffwechsel	Insuline	Antidiabetika, Insulinanaloga	A10AB
298	INSULIN HUMAN	Glucosestoffwechsel	Insuline	Antidiabetika, Insulinanaloga	A10AB, A10AC,
299	INSULIN LISPRO	Glucosestoffwechsel	Insuline	Antidiabetika, Insulinanaloga	A10AB, A10AC,
300	INSULIN NPH	Glucosestoffwechsel	Insuline	Antidiabetika, Insulinanaloga	A10AB
301	LINAGLIPTIN	Glucosestoffwechsel	Dipeptidylpeptidase-4 (DPP-4)-Inhibitoren	Orale Antidiabetika	A10BH
302	LIRAGLUTID	Glucosestoffwechsel	Glucagon-like peptide 1 receptor (GLP-1R)-Agonisten	Antidiabetika, Inkretin-Mimetikum, Gewichtsreduktion	A10BJ
303	LIXISENATIDE	Glucosestoffwechsel	Glucagon-like peptide 1 receptor (GLP-1R)-Agonisten	Antidiabetika, Inkretin-Mimetikum, Gewichtsreduktion	A10BJ
304	PIOGLITAZONE	Glucosestoffwechsel	Peroxisomaler Proliferator-aktivierter Rezeptors-gamma (PP	Orale Antidiabetika	A10BG
305	SAXAGLIPTIN	Glucosestoffwechsel	Dipeptidylpeptidase-4 (DPP-4)-Inhibitoren	Orale Antidiabetika	A10BH
306	SEMAGLUTID	Glucosestoffwechsel	Glucagon-like peptide 1 receptor (GLP-1R)-Agonisten	Antidiabetika, Inkretin-Mimetikum, Gewichtsreduktion	A10BJ
307	SITAGLIPTIN	Glucosestoffwechsel	Dipeptidylpeptidase-4 (DPP-4)-Inhibitoren	Orale Antidiabetika	A10BH
308	SOTAGLIFLOZIN	Glucosestoffwechsel	SLC5A2/Sodium dependent glucose co-transporter 2 (SGLT-2	Orale Antidiabetika, Herzinsuffizienztherapeutika, Therapeutika bei chronisc	A10BK

For Comparison: EMA Critical Medicines List - First Version 12. decembre 2023 (excerpt)

2	    		
3			
4			
5			
6			
7			
8	EMA/528805/2023		
9	6 December 2023		
10			
11	Union list of critical medicines - version 1		
12			
13			
14	ATC level 5	ATC description The Anatomical Therapeutic Chemical code: a unique code assigned to a medicine according to the organ or system it works on and how it works. The classification system is maintained by the World Health Organization (WHO).	Date of inclusion
15	A - Alimentary tract and metabolism		
16	A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)		
17	A02BC05	ESOMEPRAZOLE	1 December 2023
18	A03B - Belladonna and derivatives, plain		
19	A03BA01	ATROPINE	1 December 2023
20	A03F - Propulsives		
21	A03FA01	METOCLOPRAMIDE	1 December 2023
22	A07A - Intestinal antiinfectives		
23	A07AA09	VANCOMYCIN	1 December 2023
24	A07AA12	FIDAXOMICIN	1 December 2023
25	A07B - Intestinal adsorbents		
26	A07BA01	MEDICINAL CHARCOAL	1 December 2023
27	A10A - Insulins and analogues		
28	A10AB01	INSULIN HUMAN (fast-acting)	1 December 2023
29	A10AC01	INSULIN HUMAN (intermediate-acting)	1 December 2023
30	A10AD01	INSULIN HUMAN (intermediate - or long-acting combined with fast-acting)	1 December 2023
31	A12C - Other mineral supplements		
32	A12CC02	MAGNESIUM SULFATE	1 December 2023
33	A16A - Other alimentary tract and metabolism products		
34	A16AB02	IMIGLUCERASE	1 December 2023

<https://www.ema.europa.eu/en/news/first-version-union-list-critical-medicines-agreed-help-avoid-potential-shortages-eu>

DGIM - List of essential medicines for Internal Medicine

Proposal to develop a European perspective in cooperation with EFIM

- DGIM would like to hear about similar initiatives from EFIM member societies.
- Possible collaboration on a joint EU-centric publication?

Please contact us at info@dgim.de

For the DGIM Working Group:
Prof. Dr. Tilman Sauerbruch
Prof. Dr. Georg Ertl
Dr. med. Thomas Gamstätter



DGIM Congress 03rd-6th May 2026

Wiesbaden, Germany

President 2026: Prof. Dr. Dr. Führer-Sakel

Partner Country: **Europe**

International speakers welcome!

www.dgim.de